Biostage names regenerative medicine expert to board

BY Zachary Comeau

Charles Cox.

Holliston biotech Biostage has appointed another medical professional to its scientific advisory board as the company continues its makeover following a near bankruptcy position just months ago. 
Charles Cox, director of the children’s regenerative medicine program at University of Texas Health McGovern Medical School, was appointed to the board.
Since a $4.2-million investment largely from a group of Chinese investors in the fall, the company has begun a shift to focus on developing bioengineered organ implants to treat conditions of the throat in children.
Cox’s experience in pediatric, surgical, cell therapy and cell-based tissue engineering make him particularly well-suited to help guide the company’s scientific ventures, said board Co-Chairman Stephen Badylak. 
The company already has a relationship with Cox’s program. In August, the company announced the use of an esophageal implant in a patient at the University of Texas Health Science Center.
Cox joins Badylak, Joseph Vacanti, and Christine Finck, the last of whom is executive vice president and surgeon-in-chief at Connecticut Children’s Medical Center. 
Finck was appointed to the board last month, after her hospital invested $100,000 into the company.
“Our technology's ability to attract this prestigious group of experts to our Scientific Advisory Board is a testament to our technology's potential,” said Biostage CEO Jim McGorry.